New antibody drug shows promise for Hard-to-Treat multiple myeloma
NCT ID NCT04083534
First seen May 09, 2026 · Last updated May 09, 2026
Summary
This study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safety and see if the drug could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Study Site
Indianapolis, Indiana, 46202, United States
-
Regeneron Study Site
Ann Arbor, Michigan, 48109, United States
-
Regeneron Study Site
Rochester, Minnesota, 55905, United States
-
Regeneron Study Site
New York, New York, 10029, United States
-
Regeneron Study Site
Dallas, Texas, 75390, United States
-
Regeneron Study Site
Houston, Texas, 77030, United States
-
Regeneron Study Site
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.